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Abstract Isoform 4 of the human peptidylarginine
deiminase (hPAD4) enzyme may be responsible for the
citrullination of antigens in rheumatoid arthritis (RA) and
has been shown to be itself the target of disease-speciﬁc
autoantibodies. Here, we have tested whether the level of
serum anti-hPAD4 antibodies in RA patients is stable over
a period of 10 years and whether the antibodies inﬂuence
hPAD4-mediated deimination of the small substrate N-a-
Benzoyl-L-arginine ethyl ester. RA sera (n = 128) obtained
at baseline and after 10 years were assessed for anti-
hPAD4 antibodies by a speciﬁc immunoassay. For 118 RA
patients, serum anti-hPAD4 IgG levels were stable over
10 years. Seven patients who were negative for anti-PAD4
IgG at baseline had become positive after 10 years. Fur-
ther, total IgG from selected RA patients and controls were
puriﬁed, and a fraction was depleted for anti-hPAD4 anti-
bodies. Kinetic deimination assays were performed with
total IgG and depleted fractions. The kcat and Km values of
hPAD4-mediated deimination of N-a-Benzoyl-L-arginine
ethyl ester were not affected by the depletion of the anti-
hPAD4 antibodies from the total IgG pool. In conclusion,
RA patients remain positive for anti-hPAD4 antibodies
over time and some patients who are initially anti-hPAD4
negative become positive later in the disease course. The
anti-hPAD4 antibodies did not affect the enzymatic activity
of hPAD4 when the small substrate N-a-Benzoyl-L-arginine
ethyl ester was used. However, this ﬁnding may not exclude
an effect of these autoantibodies on citrullination of protein
substrates in RA.
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Introduction
RA is a common, complex autoimmune disorder charac-
terized by a chronic and destructive inﬂammation localized
in the synovial lining of diarthrodial joints [1]. Accumu-
lated evidence suggests that the inﬂammatory response in
the rheumatoid joints is driven by antigen-speciﬁc T cells
and B cells. The disease-causing antigens are not known,
but it appears that disease-speciﬁc B cells produce anti-
bodies speciﬁc to citrullinated proteins [1, 2]. These anti-
citrullinated protein antibodies (ACPA) represent disease-
speciﬁc markers used for the diagnosis of RA, which can
appear several years before the onset of the disease and
whose presence is associated with a more severe disease
course [3, 4]. Protein-bound arginine residues are deimi-
nated to citrulline by the Ca
2?-dependent peptidylarginine
deiminase family, of which the human isoform 4 (hPAD4)
is a target of autoantibodies in RA patients [5–9]. We have
recently shown in a large RA cohort that the presence of
anti-hPAD4 autoantibodies at baseline is associated with
radiographic damage after 10 years [6]. It is not known
why serum anti-hPAD4 antibodies are associated with a
more aggressive disease course.
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DOI 10.1007/s00296-010-1765-yIn the present work, we have addressed two key issues
related to the anti-hPAD4 immune response in RA. We
have investigated whether the level of serum anti-hPAD4
IgG is stable over a period of 10 years and tested the
possibility that the antibodies could contribute to the for-
mation of citrullinated epitopes by affecting the activity of
the enzyme.
Materials and methods
Chemicals
N-a-Benzoyl-L-arginine ethyl ester (BAEE), b-NADH,
glutathione, a-ketoglutaric acid, isopropyl b-D-thiogalac-
topyranoside (IPTG), bovine liver glutamate dehydroge-
nase (GDH), and 3-[N-morpholino] propane sulfonic acid
(MOPS) were from Sigma–Aldrich (St-Louis, USA). Glu-
tathione-Sepharose 4B, Pre-scission protease, and Protein
G Sepharose
TM 4 Fast Flow were from GE Healthcare Bio-
Sciences AB (Uppsala, Sweden). BCA reagents were from
Pierce (Rockford, USA).
Patients and sera
Serum samples from baseline and after 10 years were
available from 128 patients in the previously described
Norwegian EURIDISS cohort [6]. At baseline, these
patients had a disease duration of 2.5 (±1.2) years. The
control group (n = 120) consisted of healthy individuals
selected from the population register after matching for
age, sex, and residential area with patients in the Oslo RA
register.
hPAD4 and the anti-hPAD4 antibody assay
The full-length hPAD4 cDNA was provided by Dr. Akihito
(Tokyo Metropolitan Institute of Gerontology, Japan),
expressed as a fusion protein with glutathione S-transferase
(GST) and puriﬁed as previously described [6, 10]. For an
aliquot of hPAD4, GST was cleaved off by Pre-scission
protease. Enzymatic activities were tested with BAEE and
proteins (ﬁbrinogen, ovalbumin, catalase) as substrates,
using a colorimetric assay [11] and the Anti-Citrulline
(modiﬁed) Detection Kit (Millipore/Temecula, CA/USA),
respectively. Serum anti-hPAD4 IgG antibodies were
detected by our previously described hPAD4-speciﬁc
immunoassay [6].
IgG puriﬁcation
Five serum samples exhibiting high levels of anti-hPAD4
IgG and two sera negative for anti-hPAD4 IgG were
selected from the Oslo RA registry cohort [6]. Three con-
trols were selected from the healthy control group. Total
IgG was puriﬁed using Sepharose beads conjugated with
protein G according to the manufacturer’s instructions. IgG
was eluted with 5 9 100 ll 0.1 M glycine/HCl pH 2.5 and
collected in the tubes containing 8 ll 1 M Tris/HCl pH9.0
to neutralize the pH. Puriﬁed IgG was dialyzed against
100 mM MOPS pH 7.4, and protein concentration was
determined by the method of Bradford using a BCA kit and
human immunoglobulins as a standard (Octapharma A.S.,
Norway). Purity was conﬁrmed by SDS–PAGE.
Depletion of anti-hPAD4 antibodies from total IgG
Puriﬁed total IgG was dialyzed against 100 mM MOPS pH
7.4/1.5 mM Ca
2?. In order to deplete anti-hPAD4 IgG, the
dialyzed samples were passed through an afﬁnity column
consisting of puriﬁed GST-hPAD4 bound to glutathione-
Sepharose 4B. Two mock depletion controls were inclu-
ded: a fraction of the total IgG was passed through a glu-
tathione-Sepharose 4B column and the MOPS/Ca
2? buffer
was passed through a GST-hPAD4-glutathione-Sepharose
4B column. Depletion efﬁciency was veriﬁed by the
hPAD4-speciﬁc immunoassay.
Kinetic assay
The ammonium-release assay has been described previ-
ously [10]. Brieﬂy, the reaction mixtures (ﬁnal volume of
60 ll) contained 100 mM MOPS pH 7.4, 1 mM b-NADH,
10 mM a-ketoglutaric acid, 3.95 U GDH, 1.5 mM Ca
2?,
1 lg puriﬁed hPAD4 (0.18 U), and different amounts of the
substrate BAEE (0–10 mM). GDH, b-NADH, and a-keto-
glutarate solutions were freshly prepared, and reactions
were carried out in Maxisorp 96-well plates (Nunc,
Rochester, USA). Mixtures were pre-incubated for 10 min
at 37C in the presence of 110 lg/ml puriﬁed IgG, and
reactions were started by the addition of BAEE. Decrease
in absorbance at 340 nm was measured in a 1420 VIC-
TOR
3TM multilabel counter (Perkin-Elmer, Wallac,
Finland). b-NADH concentration was determined based on
a b-NADH standard curve (0–1 mM). Initial velocities
obtained from these experiments were plotted over
the substrate concentration (Michaelis–Menten plot).
Experiments without BAEE were carried out to control
for citrullination of proteins present in the assay (IgG,
GDH, hPAD4), which would alter the kinetics (data not
shown).
Statistical analyses
Analyses were performed using GraphPad InStat version
3.06 for Windows, GraphPad Software (San Diego, USA).
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Anti-hPAD4 IgG in RA sera at baseline
and after 10 years
To ensure a low inter-assay variability of our assay, the 128
baseline RA sera were retested and the measured levels of
anti-hPAD4 IgG antibodies were compared with our pre-
viously published data [6]. Reproducibility of data was
conﬁrmed by a linear correlation test (r = 0.96) (Fig. 1). In
the majority of the 128 RA patients, we observed that the
baseline levels of anti-hPAD4 IgG antibodies remained
stable over 10 years (Fig. 2a). Three sera that had low
levels of anti-hPAD4 IgG at baseline had become negative
at 10 years. Interestingly, seven sera, which were anti-
hPAD4 negative at baseline, had become positive after
10 years (Fig. 2b). Among these, four sera were anti-CCP2
positive at baseline and after 10 years. Radiographic joint
damage data after 10 years were available for six of these
seven patients and showed that ﬁve out of these six had
severe erosive disease with a total van der Heidje modiﬁed
Sharp score above 30 (data not shown). As shown in our
previous study, anti-hPAD4 IgG levels correlate with the
levels of anti-CCP antibodies and a higher longitudinal
radiographic damage score [6].
Inﬂuence of anti-hPAD4 antibodies on hPAD4 catalytic
activity
The range of anti-hPAD4 IgG concentrations used in the
kinetic assay was chosen according to the method
employed by Kiraly et al. [12]. First, puriﬁed IgG was
titrated in the hPAD4-speciﬁc immunoassay in order to
determine the IgG concentration that gave maximal
absorbance. To ensure sufﬁcient concentrations of anti-
hPAD4-speciﬁc antibodies in the hPAD4 kinetic assay, we
applied a concentration of puriﬁed IgG that was 30-fold
higher than the value determined by these titration exper-
iments (i.e., 110 lg/ml). In additional control experiments,
concentrations as high as 400 lg/ml of puriﬁed IgG were
tested.
The puriﬁed serum IgG fractions were then subjected to
depletion of anti-hPAD4 antibodies. As evaluated by the
hPAD4-speciﬁc immunoassay, this procedure resulted in
quantitative removal of anti-hPAD4 IgG (Fig. 3a). The
effects of the puriﬁed serum IgG fractions and of the anti-
hPAD4-depleted IgG fractions on hPAD4 activity were
assessed by the ammonium-release assay. The kcat and Km
values for hPAD4-catalyzed deimination of BAEE were
determined in the presence of total IgG fractions or IgG
fractions depleted from anti-hPAD4. To ensure that the
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Fig. 1 Inter-assay variability of the anti-hPAD4 immunoassay. The
level of anti-hPAD4 IgG (expressed as emission signals) was assessed
at baseline in sera from 128 patients in the EURIDISS RA cohort, and
the results were compared with our previously published data on the
same sera. The correlation analysis (r = 0.96) conﬁrmed that the
results were reproducible
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Fig. 2 a Assessment of serum anti-hPAD4 IgG levels in RA sera at
baseline and after 10 years. The sera were diluted 1:2,000 before
incubation, measurements were taken in duplicates, and the anti-
hPAD4 IgG levels are expressed as the mean emission signal after
subtraction of the background signal. b Assessment of serum anti-
hPAD4 IgG levels in RA sera at baseline and after 10 years. Depicted
are the three patients who were anti-hPAD4 positive at baseline and
negative after 10 years, and the seven patients who were anti-hPAD4
negative at baseline and positive after 10 years. The sera were diluted
1:2,000 before incubation, measurements were taken in duplicates,
and the anti-hPAD4 IgG activity levels are expressed as the mean
emission signal after subtraction of the background signal
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123depletion procedure itself did not affect the measured
kinetic parameters, we also performed the assay in the
presence of mock-depleted IgG. Interestingly, similar kcat/
Km values were found under all these conditions (Fig. 3b
and Table 1), suggesting that anti-hPAD4 antibodies do not
interfere with enzymatic activity.
Discussion
The role of hPAD4 in RA has been extensively studied
during the last years. Several studies found an association
between polymorphisms in the hPAD4 gene and disease
risk [8, 13–15]. Furthermore, antibodies directed against
hPAD4 have been identiﬁed and shown to be associated
with anti-CCP positivity, progressive disease, and also
persistent radiographic damage in RA patients receiving
anti-TNF-a therapy [6, 8].
We have previously shown anti-hPAD4 data at baseline
from 237 patients in the EURIDISS RA cohort [6]. Now,
we present the 10-year follow-up data on 128 patients from
this EURIDISS cohort which show that individual RA
patients have remarkably stable titers of anti-PAD4 anti-
bodies. Only seven RA patients who were initially anti-
hPAD4 negative had become positive at follow-up. It is
interesting, however, to note that disease progressed in ﬁve
of six of these patients from whom we had radiographic
joint damage data.
Serum anti-hPAD4 IgG, similarly to the anti-CCP
antibodies [16], appears early in the disease course and
remains present in the serum over time. Whether they
contribute to the chronicity of the disease is unclear. We
hypothesized that the antibodies could inﬂuence the
activity of the enzyme in vivo and thereby modulate the
protein citrullination process. For other human diseases,
such as Wegener’s granulomatosis and autoimmune thy-
roiditis, it has been suggested that the binding of speciﬁc
antibodies to enzymes affects the activity of the enzyme
[17, 18]. However, under our experimental conditions, we
did not ﬁnd that the anti-hPAD4 IgG antibodies had an
effect on hPAD4-mediated deimination of a model sub-
strate. This result does not exclude that anti-hPAD4
antibodies may have effects on the enzyme in vivo. It is,
for instance, possible that the binding of the anti-hPAD4
antibodies may stabilize the enzyme and protect it from
degradation. An alternative explanation might be that
PAD4-containing immune complexes have pro-inﬂam-
matory properties that contribute to the more pronounced
joint erosion observed in the anti-hPAD4-positive
patients.
In contrast to our results, Auger et al. [19] recently
published that anti-hPAD4 antibodies inhibit hPAD4-
mediated citrullination of ﬁbrinogen. It should be noted
that they used an approach different from ours to address
the effect of those antibodies on hPAD4 activity.
Whereas Auger et al. used a protein substrate of hPAD4,
our experiments were carried out with the small argi-
nine-derivative BAEE. As anti-PAD4 autoantibodies may
not only directly inﬂuence the enzymatic activity but
could also interfere with substrate binding, the small
BAEE molecule may still be able to enter the active site
whereas binding of the large substrate ﬁbrinogen may be
sterically blocked. Notably, antibody binding to the
C-terminal part of PAD4, which contains the active site
[20], has been demonstrated [8, 19]. Secondly, Auger
b
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Fig. 3 a Detection of anti-hPAD4 antibodies in serum, in total IgG
puriﬁed from the same serum, in serum depleted from anti-hPAD4
antibodies, and in mock depletion controls. The hPAD4-speciﬁc
ﬂuorometric immunoassay was used, and results from three individual
sera are shown; patients RA64 (anti-hPAD4 positive) and RA39 (anti-
hPAD4 negative) and the healthy control HC80. The sera and the IgG
fractions were diluted 1:2,000 before incubation. b Inﬂuence of anti-
hPAD4 antibodies on hPAD4-mediated deimination of BAEE. Shown
are the relative kcat/Km values for the total IgG fraction, IgG depleted
from anti-hPAD4 antibodies, and the mock-depleted total IgG. Data
are shown for ﬁve anti-hPAD4-positive and two anti-hPAD4-negative
RA patients and for three healthy controls. The kcat/Km value for each
total IgG fraction was normalized to one. All the experimental kcat/Km
values are provided in Table 1. (*) kcat/Km value was not determined
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123et al. puriﬁed hPAD4-speciﬁc antibodies using hPAD4
adsorbed to the surface of ELISA plates, whereas we
used sera depleted from hPAD4 antibodies by capturing
them on a GST–PAD4 afﬁnity matrix. It might therefore
be that the antibodies explored in both studies fall into
two populations that are not exactly identical. For
example, absorption of PAD4 to the plate may induce
changes in the enzyme’s tertiary structure [21] that is
likely to affect the binding of antibodies directed against
conformational epitopes. Although a direct comparison
of the results obtained from both studies appears difﬁ-
cult, they can be considered as supplementary data
describing the inﬂuence of anti-PAD4 autoantibodies on
the enzymatic activity.
In conclusion, we conﬁrm that anti-hPAD4 antibodies,
which are a useful marker of disease severity in RA at
baseline, do not disappear over time. However, our study
does not show an effect of anti-hPAD4 IgG on the activity
of the hPAD4 enzyme when a small substrate is used.
Further investigations into the mechanisms that link anti-
hPAD4 antibodies to erosive disease and resistance to anti-
TNFa treatment are therefore required in the future.
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